- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06865105
Étude des thérapies ciblées pour le traitement des participants adultes souffrant d'arthrite psoriasique active
Une étude de plate-forme multicentrique de phase 2, randomisée, des thérapies ciblées pour le traitement des sujets adultes souffrant d'arthrite psoriatique active
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: ABBVIE CALL CENTER
- Numéro de téléphone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lieux d'étude
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1G 2E8
- Recrutement
- Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
-
Trois-Rivières, Quebec, Canada, G9A 3X2
- Recrutement
- Centre de Recherche Musculo-Squelettique /ID# 274397
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7H 0P4
- Recrutement
- Dr. Latha Naik Medical Professional Corporation /ID# 272803
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06001
- Recrutement
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
-
-
Auvergne-Rhône-Alpes
-
Caluire-et-Cuire, Auvergne-Rhône-Alpes, France, 69300
- Recrutement
- Infirmerie Protestante De Lyon /ID# 273731
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, France, 37170
- Recrutement
- Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
-
-
Loiret
-
Orléans, Loiret, France, 45067
- Complété
- Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, France, 33076
- Complété
- Chu Bordeaux - Hopital Pellegrin /ID# 273390
-
-
-
-
-
Budapest, Hongrie, 1027
- Recrutement
- Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
-
Budapest, Hongrie, 1023
- Recrutement
- Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Hongrie, 3529
- Recrutement
- Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
-
-
Fejér
-
Székesfehérvár, Fejér, Hongrie, 8000
- Recrutement
- Complex Rendelo Med Zrt. /ID# 272570
-
Veszprém, Fejér, Hongrie, 8200
- Recrutement
- Vital-Medicina /ID# 272855
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Pologne, 85-068
- Recrutement
- Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
-
-
Masovian Voivodeship
-
Pruszków, Masovian Voivodeship, Pologne, 05-800
- Recrutement
- MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
-
Warsaw, Masovian Voivodeship, Pologne, 02-665
- Recrutement
- Centrum Medyczne Reuma Park /ID# 273301
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Pologne, 15-351
- Complété
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
-
-
Warmian-Masurian Voivodeship
-
Elblag, Warmian-Masurian Voivodeship, Pologne, 82-300
- Complété
- Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
-
-
-
-
-
Uherské Hradiště, Tchéquie, 686 01
- Recrutement
- Medical Plus Research /ID# 272363
-
Zlín, Tchéquie, 760 01
- Recrutement
- PV Medical Services /ID# 272368
-
-
Brno-mesto
-
Brno, Brno-mesto, Tchéquie, 638 00
- Recrutement
- Revmatologie /ID# 272367
-
-
Moravian-Silesian Region
-
Hlučín, Moravian-Silesian Region, Tchéquie, 748 01
- Recrutement
- L.K.N. Arthrocentrum /ID# 272366
-
-
-
-
California
-
Huntington Beach, California, États-Unis, 92648-5994
- Recrutement
- Newport Huntington Medical Group /ID# 272764
-
Contact:
- Site Coordinator
- Numéro de téléphone: 714-923-7112
-
-
Florida
-
Avon Park, Florida, États-Unis, 33825
- Recrutement
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
-
Contact:
- Site Coordinator
- Numéro de téléphone: 863-314-8555
-
Clearwater, Florida, États-Unis, 33765
- Recrutement
- Clinical Research Of West Florida - Phase I Unit /ID# 273198
-
Orlando, Florida, États-Unis, 32819
- Recrutement
- HMD Research LLC /ID# 273086
-
Tamarac, Florida, États-Unis, 33321
- Recrutement
- West Broward Rheumatology Associates /ID# 272892
-
Tampa, Florida, États-Unis, 33606
- Recrutement
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
-
Contact:
- Site Coordinator
- Numéro de téléphone: (813) 870-1292
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
-
Skokie, Illinois, États-Unis, 60076
- Complété
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
-
Willowbrook, Illinois, États-Unis, 60527
- Recrutement
- Willow Rheumatology and Wellness /ID# 277354
-
-
Maryland
-
Cumberland, Maryland, États-Unis, 21502
- Complété
- Klein & Associates /ID# 272829
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Recrutement
- Dartmouth-Hitchcock Medical Center /ID# 272702
-
Contact:
- Site Coordinator
- Numéro de téléphone: 603-650-4717
-
-
Ohio
-
Middleburg Heights, Ohio, États-Unis, 44130
- Recrutement
- Paramount Medical Research and Consulting /ID# 272757
-
-
Pennsylvania
-
Duncansville, Pennsylvania, États-Unis, 16635
- Recrutement
- Altoona Center For Clinical Research /ID# 272593
-
Contact:
- Site Coordinator
- Numéro de téléphone: 814-296-6108
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38119
- Recrutement
- Private Practice - Dr. Ramesh C. Gupta /ID# 272897
-
-
Texas
-
Austin, Texas, États-Unis, 78745
- Recrutement
- Tekton Research - West Gate /ID# 272765
-
Frisco, Texas, États-Unis, 75035
- Recrutement
- Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
-
Houston, Texas, États-Unis, 77089-6142
- Recrutement
- Accurate Clinical Research - Houston /ID# 272754
-
San Antonio, Texas, États-Unis, 78251
- Recrutement
- Tekton Research, LLC /ID# 272901
-
Tomball, Texas, États-Unis, 77375
- Recrutement
- DM Clinical Research - Tomball /ID# 272760
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
- Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
- Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
- Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
- Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
- Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
- Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
- Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Substudy 1: Risankizumab Monotherapy
Participants will receive risankizumab |
Subcutaneous (SC) Injection |
|
Expérimental: Substudy 1: Lutikizumab Monotherapy
Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week. |
Subcutaneous (SC) Injection |
|
Expérimental: Substudy 1: Lutikizumab and Risankizumab Combination Therapy
Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Expérimental: Substudy 2: ABBV-701 Monotherapy
Participants will initially receive ABBV-701. |
Subcutaneous (SC) Injection |
|
Expérimental: Substudy 2: Risankizumab Monotherapy
Participants will receive risankizumab. |
Subcutaneous (SC) Injection |
|
Expérimental: Substudy 2: ABBV-701 and Risankizumab Combination Therapy
Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Expérimental: Substudy 3: ABBV-547 Dose A
Participants will receive ABBV-547 Dose A. |
Subcutaneous (SC) Injection |
|
Expérimental: Substudy 3: ABBV-547 Dose B
Participants will receive ABBV-547 Dose B. |
Subcutaneous (SC) Injection |
|
Expérimental: Substudy 3: ABBV-547 Dose C
Participants will receive ABBV-547 Dose C. |
Subcutaneous (SC) Injection |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Délai: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:
|
At Week 16
|
|
Number of Participants With Adverse Events (AEs)
Délai: Up to Week 52
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Week 52
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Délai: At Week 16
|
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Délai: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Délai: At Week 16
|
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
|
At Week 16
|
|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Délai: At Week 16
|
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%. |
At Week 16
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies osseuses
- Maladies musculo-squelettiques
- Arthrite
- Maladies articulaires
- Maladies de la colonne vertébrale
- Spondylarthropathies
- Maladies de la peau, papulosquameuses
- Maladies de la peau
- Spondylarthrite
- Spondylarthrite
- Psoriasis
- Maladies de la peau et du tissu conjonctif
- Arthrite, Psoriasique
- risankizumab
- lutitizumab
Autres numéros d'identification d'étude
- M25-191
- 2024-519291-11 (Substudy 1) (Autre identifiant: EU CT)
- 2026-525937-21 (Substudy 2) (Autre identifiant: EU CT)
- 2026-527719-41 (Substudy 3) (Autre identifiant: EU CT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Délai de partage IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critères d'accès au partage IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .